Volume 9 Issue 3 (September 2025) (in progress)

The deep integration of AI and immunotherapy is reshaping the paradigm of cancer diagnosis and treatment. From biomarker discovery to personalised treatment, from adverse reaction warnings to empowering grassroots communities, despite bottlenecks such as data silos, algorithm transparency, and ethical controversies, the technical potential of AI has already begun to emerge. This paper examines the evolution of global AI medical device policies and product release trends over the past decade, identifying the issues and challenges posed by the current regulatory landscape, including: first, the structural imbalance between the regulatory system and the rate of technological innovation; second, the double-standardisation dilemma between risk classification and clinical validation; and third, the ethical paradox of data governance and algorithmic transparency. The challenges faced include: first, Technology Fusion: AI at the Crossroads with Synthetic Biology and Nanotechnology. Second, Algorithm Transparency and Ethical Paradox. Third, In-Depth Application of Regulatory Technology. Fourth, Collaborative Innovation in Industrial Ecology. Based on this, this paper provides systematic recommendations for addressing the regulation of AI medical devices: first, Building a Dynamic Adaptive Technology Supervision System. Second, Perfecting the Full Life Cycle Clinical Evidence Chain. Third, Create an Open and Collaborative Industrial Innovation Ecosystem. Fourth, Deepen International Regulatory Coordination and Cooperation. Recommendations for the regulation of AI medical devices in the field of immunotherapy: First, Multi-Modality Imaging and Treatment Integrated Platform. Second, Intelligent Empowerment of Primary Care. Third, Global Collaboration and Data Sharing.

Research indicates that immunization is the most efficacious approach for stopping the transmission of COVID-19. This study aims to offer immunization recommendations for patients with autoimmune/autoinflammatory rheumatological disorders, immunodeficiencies, cancer, diabetes, chronic respiratory, and cardiovascular diseases. The intended audience includes doctors, medical personnel, and patients. This review study involved conducting a search in scholarly electronic databases, including ISI, Google Scholar, Scopus, and PubMed. The issue of COVID-19 vaccinations and the vaccination of patients with certain disorders was informed by the latest and pertinent authoritative publications published between 1980 and 2024. When autoimmune illness patients effectively manage their disease activity and there is no concurrent infection, they should receive the COVID-19 vaccination. Low-intensity immunosuppression does not reduce the antibody response to vaccinations. Immunization using all forms of vaccination, excluding live attenuated vaccines, is efficacious for all individuals with cancer, except for those undergoing anti-B cell therapy. Additionally, it is recommended to administer vaccinations to individuals who have underlying conditions such as obesity, cardiovascular diseases, respiratory diseases, and diabetes, as these conditions heighten the chance of developing severe cases of COVID-19. To combat the COVID-19 virus, the most effective approach is to increase vaccination coverage in order to stimulate immune responses. This paper provides a thorough examination of the latest developments and existing challenges in the area of COVID-19 vaccines against cancer. Additionally, it explores the prospective future uses of vaccines in cancer immunotherapies.

The microbiota plays an essential role in the regulation of the natural immune system, influencing both innate and adaptive immunological responses. This review extracted information from available observational studies that explore the intricate cooperation between gut microbiota and immune system regulation across various health conditions, including Crohn’s disease, respiratory infections, autoimmune diseases, cancer, metabolic disorders, and infectious diseases. Key findings highlight how dysbiosis, a rotation in the microbiome composition or microbial imbalance, contributes to disease pathogenesis and immune dysregulation, while specific microbial taxa and their metabolites can serve as potential biomarkers and therapeutic targets. By analyzing these studies, the paper aims to provide a comprehensive understanding of the gut microbiota’s impact on immune function and its potential implications for disease prevention and management. In conclusion, this review comprehensively elucidates the complex relationship between gut flora and immune system regulation across various health conditions. The synthesized findings underscore the profound impact of microbiota composition on immune responses, from influencing disease susceptibility and severity to potential therapeutic interventions. Key insights include the identification of microbiota-based biomarkers for predicting treatment outcomes and disease risks, highlighting the potential for personalized medicine approaches. However, the few available observational studies, such as study design variability and the complex nature of microbiota dynamics, necessitate further mechanistic research to validate causal relationships and optimize clinical applications. Moving forward, integrating microbiota-targeted therapies and dietary interventions tailored to individual microbial profiles holds promise for mitigating immune dysregulation and improving overall health outcomes.

Autoimmune disorders comprise a broad category of illnesses marked by abnormal immune reactions against self‑antigens, resulting in persistent inflammation and tissue damage. This comprehensive review examines the complex mechanisms underlying the development of autoimmune disease, focusing on immunopathogenesis. We discuss the interplay between genetic predispositions, environmental triggers, and pathogens in the initiation and perpetuation of autoimmunity. Key cytokines and inflammatory pathways are highlighted to illustrate their roles in disease progression. We then explore the distinct pathogenic mechanisms of organ‑speciϐic autoimmune disorders, including autoimmune thyroid diseases, autoimmune hemolytic anemia, neuromyelitis optica, idiopathic inflammatory myopathies, and inflammatory bowel disease, while also reviewing the influence of gut microbiome dysbiosis on immune function. Lastly, we address biomarker identiϐication for early detection, current therapeutic strategies, and emerging treatments that target novel pathways. By integrating ϐindings from diverse studies, this review provides a holistic understanding of the immunological landscape of autoimmune disorders, paving the way for improved diagnostic and therapeutic options

The SARS-2 virus, responsible for the COVID-19 epidemic in early 2020, persists in posing a hazard to public health through the emergence of new mutations and surges in prevalence across several nations. Immunosuppressive medications treat both short-term and long-term inflammatory illnesses. The classification of these medications into various types is based on their action mechanisms. It is important to review the most recent data on the effectiveness and side effects of administering these drugs to patients because of the risk of severe inflammatory repercussions in COVID-19 patients, including acute respiratory failure and cytokine storm. This article presents accurate data on the advantages and disadvantages of using immunosuppressive medications in COVID-19 patients, while also providing a concise overview of the various types of these medications. Taken together, anti-inflammatory drugs and immune response inhibitors seem to be associated with better outcomes, such as shorter hospital stays and less need for mechanical ventilation, faster recovery from acute symptoms, and lower mortality rates, especially in the critically ill. However, one must consider the possibility of increasing treatment duration and vulnerability to fungal and bacterial infections. To minimize the negative effects of these medications, it is important to carefully balance their dosage and administration timing. Overall, the utilization of immunosuppressive medications, whether administered recently during illness or consistently for non-COVID-19 reasons, appears to have a beneficial impact on managing inflammation, expediting recovery, and decreasing mortality. However, it is crucial to exercise caution and avoid prescribing these drugs without proper consideration.

Millions of people worldwide suffer from diabetes, and many develop chronic wounds like diabetic foot ulcers that struggle to heal. Traditional wound dressings often fall short. They cannot effectively control infections or create the ideal conditions for healing. This is where gelatin-based biofilms come in. Made from collagen, gelatin is naturally compatible with the human body and can be tailored to meet the specific needs of diabetic wounds. This overview explores how gelatin-based biofilms are revolutionising wound care. Recent advances in gelatin-based biomaterials demonstrate significant promise for improving wound healing outcomes. Studies show these materials achieve 50–100% wound closure within 12–18 days, with gelatin-QAS/PCL/bioglass nanofibers and GelMA/graphene oxide composites showing remarkably rapid healing. The materials exhibit strong antibacterial properties against common pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA)and E. coli, while maintaining excellent cell viability above 80%. Mechanical testing reveals favourable properties, including compressive strength of up to 412 kPa and porous structures that are ideal for tissue regeneration. Key findings include enhanced granulation tissue formation (reaching a thickness of 1.6 mm), reduced wound areas (remaining at just 4.9% after treatment), and promotion of neurovascular regeneration. The evidence suggests gelatin-based biomaterials are ready for more extensive clinical validation, with future research needed to optimise degradation rates and transition these promising results into clinical practice. They are paving the way for real-world solutions that could transform the lives of people with diabetes. By combining nature’s building blocks with cutting-edge science, these advanced dressings offer hope for faster, safer, and more effective wound healing.

Infertility remains a significant global health concern, with endometrial receptivity recognized as a critical factor influencing successful implantation. Granulocyte‑Colony Stimulating Factor (G‑CSF), a hematopoietic cytokine, has recently emerged as a potential therapeutic agent for enhancing endometrial function and modulating immune responses during assisted reproductive procedures. This study aims to investigate the effect of intrauterine infusion versus subcutaneous injection of G‑CSF on immunological and angiogenic markers related to endometrial receptivity in infertile women undergoing intrauterine insemination (IUI). A total of 75 infertile females were enlisted in this prospective interventional comparative trial and were equally divided into three groups: the intrauterine infusion group, the subcutaneous injection group, and the control group (no G‑CSF administration). Baseline demographic and hormonal characteristics, as well as ultrasound and immunological parameters, were recorded before and after G‑CSF administration. Statistical analysis showed no significant differences in demographic and baseline clinical, hormonal, and biochemical characteristics across the groups. Post‑intervention, both G‑CSF groups demonstrated significant improvements in endometrial vascularity indices (pulsatility index, resistance index, and V1/V2 ratio) compared to the control group, despite the endometrial thickness not differing significantly. Serum levels of TNF‑α significantly decreased, while VEGF levels increased significantly post‑G‑CSF in all groups; IL‑10 levels increased but reached significance only in the subcutaneous and control groups. These outcomes indicate that G‑CSF may enhance endometrial receptivity via improved vascular and immunological parameters, although the effect remains inconclusive and requires further validation.

Rabies is still a serious public health problem globally, especially where there is high dog-to-human contact and low vaccination coverage. In this paper, a fractional-order mathematical model is developed to explain the transmission dynamics of rabies in dogs and humans. The model is established by adopting the Caputo-Fabrizio fractional-order derivative (CFFROD), which suits the memory effects and non-locality properties of disease progression. The model has compartments for susceptible, exposed, infected, and recovered members of both species, as well as the viral load in the environment. Existence and uniqueness of solutions are proven via fixed-point theory to ensure mathematical consistency of the model. Numerical computations via the Adams-Bashforth method are performed to analyse the dynamics of the system for a range of fractional orders. Numerical computations provide evidence that fractional-order dynamics have a considerable impact on disease progression, ensuring the significance of memory in infectious disease modelling. Based on verified experimental data, a comparison between the fractional-order and classical models is presented. The results show that the fractional model provides greater insight into transmission and control timing patterns and best fits real-world data. This study supports the use of fractional modelling in the well-informed creation of successful rabies prevention initiatives and improved comprehension of disease dynamics.